Celon Laboratories Profile
Key Indicators
- Authorised Capital ₹ 233.10 Cr
- Paid Up Capital ₹ 53.34 Cr
- Company Age 24 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 46.00 Cr
- Satisfied Charges ₹ 701.32 Cr
- Revenue Growth -54.48%
- Profit Growth -192.22%
- Ebitda -163.62%
- Net Worth -32.10%
- Total Assets -13.78%
About Celon Laboratories
Celon Laboratories Private Limited (CLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 23 January 2001 and has a history of 24 years. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Medvin Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 233.10 Cr and a paid-up capital of Rs 53.34 Cr.
The company currently has active open charges totaling ₹46.00 Cr. The company has closed loans amounting to ₹701.32 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Celon Laboratories Private Limited India is Chinta Shalini as COMPANY SECRETARY. Mohammad Alwazir, Ajay Bhatia, and Hocine Said serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232TG2001PTC036097
- Company No.
036097
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2001
- Date of AGM
25 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Celon Laboratories Private Limited offer?
Celon Laboratories Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, ISO & Quality Management Consultants, Certification Services, TB, Tumor & Cancer Drugs, Anti Cancer Medicines.
Who are the key members and board of directors at Celon Laboratories?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ajay Bhatia ![]() | Managing Director | 02-May-2024 | Current |
Chinta Shalini | Company Secretary | 28-Sep-2022 | Current |
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mohammad Alwazir ![]() | Director | 13-Nov-2020 | Current |
Hocine Said ![]() | Director | 13-Nov-2020 | Current |
Financial Performance of Celon Laboratories.
Celon Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 54.48% decrease. The company also saw a substantial fall in profitability, with a 192.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 32.1%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Celon Laboratories?
In 2023, Celon Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹46.00 Cr
₹701.32 Cr
Charges Breakdown by Lending Institutions
- Others : 46.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
21 Feb 2024 | Others | ₹46.00 Cr | Open |
06 Jul 2017 | Others | ₹500.00 Cr | Satisfied |
27 Feb 2015 | Export Import Bank Of India | ₹119.00 Cr | Satisfied |
25 Jun 2012 | Kotak Mahindra Bank Limited | ₹3.65 Cr | Satisfied |
27 Dec 2011 | Icici Bank Limited | ₹18.20 Cr | Satisfied |
How Many Employees Work at Celon Laboratories?
Celon Laboratories has a workforce of 535 employees as of Nov 15, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Celon Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celon Laboratories's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.